Genomic Health Inc (GHDX) Return on Investment ROI from the third quarter of 2019 to third quarter of 2018 and for the year 2019, average high and low, overall ranking from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Genomic Health Inc  (NASDAQ: GHDX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare


Genomic Health Inc's ROI from its third quarter of 2019 to the third quarter of 2018 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Genomic Health Inc's ROI in the third quarter of 2019?
Genomic Health Inc achieved a return on average invested assets (ROI) of 16.26 % in its third quarter of 2019 a new company high.

ROI has improved compared to 16.17% in the second quarter of 2019, due to net income growth.

Within the Healthcare sector 55 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2019 quarter, so far to 418, from total ROI ranking in the second quarter of 2019 at 475.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Investment Change TTM 59.04 % 54.19 % 46.49 % 34.98 % 29.22 %
Y / Y Net Income Change TTM 203.5 % 1084.89 % - - -
Investment (TTM) in Millions 403 372 343 275 250
Return On Investment (TTM) 16.26 % 16.17 % 15.48 % 10.72 % 8.52 %
GHDX's Overall Ranking # 418 # 475 # 958 # 1142 # 2450
Seq. Investment Change TTM 12.31 % 13.02 % 14.51 % 9.42 % 8.88 %
Seq. Net Income Change TTM 12.91 % 18.07 % 65.33 % 37.71 % 340.8 %
Net Income (TTM) in Millions 57 50 42 26 19

GHDX Company Profile >> Back to GHDX Roi Comparisons >> See Annual GHDX Return On Investment



Return On Investment GHDX's Ranking
Within: No.
Industry # 3
Sector # 56
Overall # 418

Return On Investment Statistics
High Average Low
16.26 %
-6.09 %
-24.76 %
(Sep 30 2019)   (Sep 30 2015)







Financial Statements
Genomic Health Inc's III. Quarter Investments $ 403 Millions GHDX's Balance sheet
Genomic Health Inc's III. Quarter Income $ 19 Millions Quarterly GHDX's Income Statement
GHDX's Income by Division See GHDX's Income by Division


GHDX Annual Return On Investment (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Investments in Millions 275 192 160 142 148
Y / Y Investment Growth 42.94 % 20.11 % 12.68 % -3.82 % 0.26 %
Net Income in Millions 26 -4 -14 -33 -25
Y / Y Net Income Growth - - - - -
Annual Return On Investment 9.35 % -2.01 % -8.7 % -23.47 % -16.66 %


Annual Roi Comment
In the fiscal year 2018 ROI improved to 9.35 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Laboratories Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GHDX's Roi Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GHDX's Competitors
Subscribers only: Roi for Genomic Health Inc's Suppliers
Subscribers only: Return On Investment for GHDX's Customers

Other Ratios
GHDX's Roa GHDX's Inventory Turnover Ratio GHDX's Growth Rates GHDX's Dividend Statistics
GHDX's Profitability Ratios GHDX's Asset Turnover Ratio GHDX's Dividend Growth
GHDX's Roe GHDX's Valuation Ratios GHDX's Financial Strength Ratios GHDX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2019, within Healthcare Sector ROI
Castle Biosciences Inc   42.65 %
Remedent Inc   42.49 %
Exelixis Inc   41.45 %
Ligand Pharmaceuticals Incorporated  38.90 %
Oramed Pharmaceuticals Inc  37.93 %
Vanda Pharmaceuticals Inc   37.58 %
Vertex Pharmaceuticals Inc  36.81 %
Strongbridge Biopharma plc  34.65 %
Harrow Inc   32.26 %
Arrowhead Pharmaceuticals Inc   31.44 %
Align Technology inc   30.40 %
Lifevantage Corp  29.12 %
Corcept Therapeutics Inc  29.06 %
Eli Lilly And Company  28.71 %
Mettler toledo International Inc   28.61 %
Fonar Corporation  28.43 %
Idexx Laboratories Inc  27.80 %
Siga Technologies Inc  25.81 %
Integrated Biopharma Inc  25.06 %
Biogen Inc   24.67 %
Chemed Corporation  23.93 %
Abiomed Inc   22.95 %
Biospecifics Technologies Corp  22.30 %
Alpha Pro Tech Ltd   20.98 %
Viemed Healthcare Inc   20.89 %
Regeneron Pharmaceuticals Inc   18.65 %
Pro dex Inc   18.42 %
Amgen Inc   18.22 %
Contrafect Corporation  17.96 %
Masimo Corp  17.60 %

Date modified: 2026-09-26T07:02:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.